Stereotaxis (NASDAQ:STXS) announced a senior management change in a move designed to help re-establish the company’s growth trajectory.Read More
Echelon Wealth Partners raised its price target for RepliCel Life Sciences (TSX-V:RP) to $2.15 from $1.50 after the company closed a unit offering that will add about $4.1-million in net cash to its balance sheet. The stock closed at $1.03 on Monday.
“The recapitalization provides funds to drive [RepliCel’s hair follicle-derived] non-bulbar dermal sheath cell platform forward with renewed vigor,” writes analyst Doug Loe, noting that he expects interim six-month data from a Phase 1/2 Achilles tendinosis/RCT-01 study by yearend.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million.
Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet indicated for major depressive disorder approved by the FDA. Patent protection for Forfivo XL in the U.S. expires in 2027, with an authorized generic entering the market in January 2018.Read More
Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday.
“We believe the company’s anticalin platform has broad potential for the long term and that the multiple partners, broad pipeline and flexibility of the platform provide investors with the potential for multiple catalysts along with partner-based non-dilutive funding,” writes analyst Joseph Pantginis.Read More